Revolution Medicines reported $197.6 million in third-quarter net product revenue from RASONQUE, its newly approved pancreatic cancer drug. The figure reflects about five weeks of US sales and more than 5,000 commercial patients. Executives cautioned that early sales included patients moving from an expanded access program and others who had run out of treatment options. Chief global commercialization officer Anthony Mancini said both groups are finite sources of demand, and it is too early to judge the launch's trajectory. The company posted a net loss of $407.5 million, up from $305.2 million a year earlier, as research and commercial spending rose. It ended the quarter with $3.7 billion in cash and marketable securities. The Food and Drug Administration approved the drug on August 26.

Revolution Medicines rises on Q3 beats; maintains 2026 guidance. * Revolution Medicines is ~~6% higher in after-hours trading Wednesday after posting Q3 financial results that beat on both lines. * The oncology therapies developer also reaffirmed full-year 2026 GAAP operating expense guidance of $2.1B-$2.2B. * Q3 GAAP EPS of -$1.90 compares to -$1.61 in the year-ago period. * Revolution noted that revenue in the quarter (ended Sept. 30) for Rasonque (daraxonrasib), its second-line therapy for metastatic pancreatic cancer approved in late August, reached $197.6M. * The company ended the quarter with cash, cash equivalents, and marketable securities of ~$3.7B compared to ~$2B on Dec. 31, 2025. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

Medicilon presents Revolution Medicines with the "Excellence in Client Partnership Award" Oct 30, 2026, 12:00 ET BOSTON, Oct. 30, 2026 /PRNewswire/ - Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration. A Three-Year Partnership Built on a Trusted R&D Model Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO-client collaboration. At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS - a target once deemed "undruggable" - and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership. In-Depth Discussions Explore New Collaboration Opportunities During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency. Laboratory Tour Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.